Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,510.00
Bid: 12,524.00
Ask: 12,526.00
Change: 118.00 (0.95%)
Spread: 2.00 (0.016%)
Open: 12,468.00
High: 12,556.00
Low: 12,434.00
Prev. Close: 12,392.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 2-Sanofi, GSK say COVID-19 vaccine booster candidate give good immune response

Wed, 15th Dec 2021 07:29

(Adds details throughout)

By Benoit Van Overstraeten

PARIS, Dec 15 (Reuters) - Sanofi and
GlaxoSmithKline said on Wednesday a single booster dose
of their COVID-19 vaccine candidate provided strong immune
responses, preliminary data from clinical trials show, a boost
for the drugmakers after lagging the vaccine race.

The French and British partners said they expected more
results of the late-stage Phase III study of their recombinant
adjuvanted COVID-19 vaccine candidate in the first quarter.

They plan to file booster data with regulatory authorities
following the Phase III results.

"The booster was well tolerated, with a safety profile
similar to currently approved COVID-19 vaccines. This is the
most comprehensive booster trial to date to explore boosting
across different vaccine technologies used for primary
vaccination", the companies said in a statement.

"To provide the necessary data to regulatory authorities for
the booster vaccine submission, the trial will continue to
accrue the number of events needed for analysis, with results
expected in Q1, 2022."

No safety concerns were identified.

The vaccine uses the same technology as one of Sanofi's
seasonal influenza vaccines coupled with an adjuvant, a
substance that acts as a booster to the shot, made by GSK.

The news provides some optimism for the companies after
falling behind rivals in the race for COVID-19 shots and big
delays with the development of this shot.

Last year, trials for the shot showed an insufficient immune
response in older people. The companies had said the vaccine
could be approved by the year-end after initially targeting the
first half of the year.

At the end of September, Sanofi dropped its plans for its
own mRNA-based COVID-19 vaccine because of the dominance
achieved by BioNTech-Pfizer and Moderna
in using the technology to fight the pandemic.

BOOSTER SHOT

The booster shot has been tested for all age groups and for
people who have received four of the most widely approved shots
- AstraZeneca, Johnson & Johnson, Moderna and
Pfizer/BioNTech - as part of their primary vaccine.

It was administered between four and ten months after a
complete primary vaccination schedule. The Omicron variant was
not circulating during the trial.

"Preliminary results from the VAT0002 clinical trial
investigating the safety and immunogenicity of the booster
showed neutralizing antibodies increased nine to 43-fold
regardless of the primary vaccine received (AstraZeneca, Johnson
& Johnson, Moderna, Pfizer/BioNTech) and for all age groups
tested", Sanofi said.

The company said this was the most "comprehensive" booster
trial to date as European countries grapple with a new wave of
COVID-19 infections fuelled by the Delta variant of the virus
and are gearing up for the new more contagious Omicron variant.

Sanofi also it was continuing "its contribution to global
public health needs" with the manufacturing of up to half a
billion doses from BioNTech/Pfizer, Moderna, and Johnson &
Johnson vaccines.

(Reporting by Benoit Van Overstraeten;
Writing by Josephine Mason
Editing by Tom Hogue and Louise Heavens)

More News
4 Apr 2024 13:09

UK shareholder meetings calendar - next 7 days

Friday 5 April 
Faron Pharmaceuticals LtdAGM
VPC Specialty Lending Investments PLCGM re capital return via B share scheme
Monday 8 April 
Premier African Minerals LtdAGM
Tuesday 9 April 
Ethernity Networks LtdEGM re board appointments and option grants
Wednesday 10 April 
Valereum PLCAGM
Wincanton PLCGM re takeover by GXO Logistics Inc
Thursday 11 April 
AstraZeneca PLCAGM
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
3 Apr 2024 22:01

Biden, Senator Bernie Sanders push companies to cut cost of asthma inhalers, prescription drugs

WASHINGTON, April 3 (Reuters) - President Joe Biden hosted a White House event with U.S. Senator Bernie Sanders on Wednesday to tout their fight against high prescription drug prices and push companies to cut the cost of inhalers for asthma sufferers.

Read more
3 Apr 2024 17:22

UK's FTSE 100 pressured by stronger pound; miners climb

FTSE 100 flat, FTSE 250 up 0.2%

*

Read more
3 Apr 2024 11:02

CORRECT: AstraZeneca, Daiichi make US progress with licence approvals

(Correcting the description of extravascular haemolysis' effects on patients with paroxysmal nocturnal haemoglobinuria)

Read more
2 Apr 2024 15:22

London close: Stocks turn red on return from Easter break

(Sharecast News) - UK stocks experienced a downturn by the end of trading on Tuesday, as investors resumed activity following the extended weekend, with initial gains reversed by the close ahead of a week marked by a number of key economic data releases.

Read more
2 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 buoyed by UK manufacturing growth

(Alliance News) - The FTSE 100 in London was up at midday on Tuesday, reacting to the UK manufacturing sector returning growth and further PMI data across the globe.

Read more
2 Apr 2024 10:25

AstraZeneca and Daiichi make US progress with latest licence approvals

(Alliance News) - AstraZeneca PLC on Tuesday noted significant progress for two of its clinical-stage treatments in the US.

Read more
2 Apr 2024 09:54

LONDON BROKER RATINGS: Bernstein starts AstraZeneca at 'outperform'

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning:

Read more
2 Apr 2024 09:09

LONDON MARKET OPEN: FTSE 100 up as oil majors and gold miners shine

(Alliance News) - Stock prices in London opened higher on Tuesday, in confident trade following the long Easter weekend, ahead of a UK manufacturing sector reading later in the morning.

Read more
2 Apr 2024 08:05

LONDON BRIEFING: HSBC in special payout on Canada sale; Astra FDA win

(Alliance News) - London's FTSE 100 traded higher on Tuesday following the long weekend, as investors react to US data, and look ahead to manufacturing sector readings from Europe later.

Read more
2 Apr 2024 07:08

US FDA gives green light for use of AstraZeneca's Voydeva

(Sharecast News) - America's drug regulator gave the green light to AstraZeneca's for the add-on use of Voydeya in the treatment of extravascular haemolysis (EVH) in patients with paroxysmal nocturnal haemoglobinuria (PNH).

Read more
27 Mar 2024 12:02

LONDON MARKET MIDDAY: FTSE 100 underperforms ahead of US PCE data

(Alliance News) - Stock prices in London were lower at midday on Wednesday, but trade was more confident in mainland Europe, with focus turning to the release of the US Federal Reserve's preferred inflation gauge on Friday.

Read more
27 Mar 2024 11:56

C4X Discovery seeks AIM delisting but half-year revenue skyrockets

(Alliance News) - C4X Discovery Holdings PLC shares plunged on Wednesday after it said it plans to delist from AIM in London, due to "the recent downturn in the financial markets" hampering its valuation.

Read more
27 Mar 2024 09:19

AstraZeneca treatments become "first and only" to be approved in Japan

(Alliance News) - AstraZeneca PLC announced on Wednesday the approval of two of its treatments for use in Japan.

Read more
27 Mar 2024 09:03

LONDON MARKET OPEN: FTSE 100 slips as unease lingers before US data

(Alliance News) - Stock prices in London edged lower after the open on Wednesday, with some nervy trade ahead of a US inflation reading later in the week.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.